VPC
BCRX icon

Vestal Point Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vestal Point Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83M Buy
8,300,000
+1,275,000
+18% +$11.5M 1.94% 19
2026
Q1 		$66.9M Buy
7,025,000
+4,775,000
+212% +$37.1M 1.87% 16
2025
Q4 		$17.6M Buy
+2,250,000
New +$16.3M 0.6% 41

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vestal Point Capital's BCRX Position: Q2 2026 in Review

Vestal Point Capital increased its BioCryst Pharmaceuticals (BCRX) stake by 18% in Q2 2026, buying an estimated $11.5M and bringing the position to 8,300,000 shares worth $83M. The position accounts for 1.94% of the portfolio, ranked #19.

Vestal Point Capital first reported a position in BCRX in Q4 2025 and has held it in 3 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Vestal Point Capital held 8,300,000 shares of BioCryst Pharmaceuticals worth $83M as of Q2 2026.
  • Vestal Point Capital bought 1,275,000 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $11.5M.
  • BioCryst Pharmaceuticals made up 1.94% of Vestal Point Capital's portfolio in Q2 2026, its #19 holding.
  • Vestal Point Capital first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.